Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been given a consensus rating of “Buy” by the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six research analysts ...
Some results have been hidden because they may be inaccessible to you